2Taucher S,Rudas M,Mader RM,et al.Influence of nevadjuvanl therapy with epirubjcin and ducetaxal on the expression of HERI/neu in patients with breast cancer[J].Breast cancer Res Trent,2003,82(3):207.
7Honkoop A H, Bakker S A, Hoekman K, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer [J]. Oncologist, 1999,4(2) : 106-111.
8Jain V, Landry M, Levine E A. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma [J]. Am Surg, 1996,62(2) : 162-165.
9Lee S H, Chung M A, Quddus M R, et al. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer [J]. Am J Surg, 2003,186 (4) : 348-350.
10Makris A, Powles T J, Allred D C, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study [J]. Breast Cancer Res Treat, 1999,53 (1):51-59.
2Lian-Ming Wu,Jia-Ni Hu,Hai-Yan Gu,Jia Hua,Jie Chen,Jian-Rong Xu.Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?[J].Breast Cancer Research and Treatment.2012(1)
3Tian-bao Wang,Xiu-qing Wei,Wei-hao Lin,Han-ping Shi,Wen-guang Dong.The inhibition of Endostar on the angiogenesis and growth of gastrointestinal stromal tumor xenograft[J].Clinical and Experimental Medicine.2012(2)
4YoshinoriHirashima,YasuhideYamada,UkihideTateishi,KenKato,MototakaMiyake,YosukeHorita,KoheiAkiyoshi,AtsuoTakashima,NatsukoOkita,DaisukeTakahari,TakakoNakajima,TetsuyaHamaguchi,YasuhiroShimada,KuniakiShirao.Pharmacokinetic parameters from 3‐Tesla DCE‐MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis[J].Int J Cancer.2012(10)
